As a conventional immunosuppressant in organ transplantation (36), sirolimus has been proved in vitro and in preclinical models for stabilizing lung function in LAM and treating extrapulmonary manifestations, such as renal angiomyolipoma, by inhibiting T- and B-lymphocyte activation via the IL-2 signaling pathway (3, 37). Here, IL2 is linked to kidney angiomyolipoma.